| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00597-0138-95 | 00597-0138 | Afatinib | Gilotrif | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug 8, 2013 | Apr 30, 2027 | In Use |
| 00597-0138-30 | 00597-0138 | Afatinib | Gilotrif | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug 8, 2013 | In Use | |
| 13668-0682-30 | 13668-0682 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Apr 12, 2023 | In Use | |
| 47335-0475-88 | 47335-0475 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 1, 2016 | In Use | |
| 00597-0137-90 | 00597-0137 | Afatinib | Gilotrif | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct 1, 2018 | May 31, 2027 | In Use |
| 72205-0080-30 | 72205-0080 | Erlotinib Hydrochloride | Erlotinib Hydrochloride | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 11, 2021 | In Use | |
| 42292-0051-05 | 42292-0051 | Erlotinib hydrochloride | Erlotinib Hydrochloride | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 28, 2019 | Jan 31, 2021 | No Longer Used |
| 43598-0600-60 | 43598-0600 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 00597-0137-30 | 00597-0137 | Afatinib | Gilotrif | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug 9, 2013 | In Use |
Found 12159 results — Export these results
Home